ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. If necessary, a new list of reported errata will be provided with each issue of *PF*. This information will also be available as a cumulative table in future *Supplements* and will appear in its corrected form in a future annual edition of *USP–NF*. An erratum consists of content erroneously published that does not accurately reflect the intended official or effective requirements as approved by the Council of Experts. USP staff is available to respond to questions regarding the accuracy of a particular requirement (call 1-800-822-USPC).

Page	Title	Section	Description
USP 32–NF 27			
2012	*Cod Liver Oil*	*Assay for vitamin D*	Under *Procedure*, line 4 from the end : Change ''in which, r_{U2} and r_{U1}'' to: in which, r_{U1} and r_{U2}
2991	*Mirtazapine Orally Disintegrating Tablets*	*Definition*	Line 3: Change ''($C_{17}H_{19}N_3$), calculated on the anhydrous basis.'' to: ($C_{17}H_{19}N_3$).
3604	*Succinylcholine Chloride*	*Chromatographic purity*	Under *Test 1*, *Buffer solution*: Change ''Prepare a solution in water containing 3.85 g per L of 1-pentanesulfonic acid,'' to: Prepare a solution in water containing 3.85 g per L of sodium 1-pentanesulfonate anhydrous,
First Supplement to USP 32–NF 27			
4042, online	*Chlorhexidine Gluconate Solution*	*Related compounds*	The gradient table under *Chromatographic system* was erroneously replaced by the gradient table under *Chromatographic system* in the *Assay*. See correct table given after this errata table.
4086	*Orbifloxacin*	*Heavy metals* ⟨231⟩	Change the section head to read: *Heavy metals, Method II* ⟨231⟩
Second Supplement to USP 32–NF 27			
4154	⟨891⟩ *Thermal Analysis*	*Transition and Melting Point Temperatures*	Table 1, 2nd row, 3rd cell: Change ''Exothermic'' to: Endothermic
4228	*Cloprostenol Injection*	*Assay*	Line 2 under *pH 2.5 Monobasic sodium phosphate solution*: Change ''2.4 mg of monobasic sodium phosphate'' to: 2.4 mg of monobasic sodium phosphate dihydrate

Second Supplement to USP 32–NF 27

Page	Title	Section	Description
4232	*Ecamsule Solution*	*Related compounds*	1st formula under *Test for Related Compound A to F, Procedure*: Change ''$100[C_S/(C_U A)](r_U/r_S)$'' to: $100[100C_S/(C_U \times A)](r_U/r_S)$
			2nd formula under *Test for Related Compound A to F, Procedure*: Change ''$100(350.43/372.41)[C_S/(C_U A)](r_U/r_S)$'' to: $100(350.43/372.41)[100C_S/(C_U \times A)](r_U/r_S)$
			1st formula under *Test for related compound G, Ecamsule exo-2-hydroxyecamsule, Ecamsule endo-2-hydroxyecamsule, and unspecified impurities, Procedure*: Change ''$100(348.41/370.40)[C_S/(C_U A)](r_U/r_S)$'' to: $100(348.41/370.40)[100C_S/(C_U \times A)](r_U/r_S)$
			2nd formula under *Test for related compound G, Ecamsule exo-2-hydroxyecamsule, Ecamsule endo-2-hydroxyecamsule, and unspecified impurities, Procedure*: Change ''$100(1/F)[C_S/(C_U A)](r_i/r_S)$'' to: $100(1/F)[100C_S/(C_U \times A)](r_i/r_S)$

Chlorhexidine Gluconate Solution, *Related compounds*

Time (minutes)	*Solution A* (%)	*Solution B* (%)	Elution
0	100	0	equilibration
0–15	100	0	isocratic
15–16	100→45	0→55	linear gradient
16–21	45	55	isocratic
21–22	45→100	55→0	linear gradient
22–27	100	0	re-equilibration

Interim Revision Announcement

USP 33–NF 28			
Page	**Title**	**Category Section**	**Description**
415	⟨891⟩ *Thermal Analysis*	*Transition and Melting Point Temperatures*	Table 1, 2nd row, 3rd cell: Change ''Exothermic'' to: Endothermic
1476	*Benzalkonium Chloride*	*Specific Tests Limit of Amines and Amine Salts*	Under category *Impurities*, add section *Organic Impurities* and move *Limit of Amines and Amine Salts* to this new section, changing its name to: *Procedure: Limit of Amines and Amine Salts*
2222	*Bupropion Hydrochloride*	*Impurities Organic Impurities*	Under *Procedure 2*: Change ''*Diluent, Solution A, Mobile phase, Solution B, Standard solution, Sample solution, Chromatographic system,* and *System suitability*'' *Diluent, Solution A, Mobile phase, Standard solution, Sample solution, Chromatographic system,* and *System suitability*
			In the formula under *Analysis*: Change ''Result = $(r_U/r_S) \times (C_S/C_U) \times 100$'' to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$ and add the definition: F = relative response factor for each impurity relative to bupropion
2606	*Cod Liver Oil*	*Assay Vitamin D*	Change the definitions of variables ''r_{U2} = peak response for cholecalciferol from *Sample solution A* r_{IS2} = peak response for ergocalciferol from *Sample solution B* r_{IS1} = peak response for ergocalciferol from *Sample solution A* r_{U1} = peak response for cholecalciferol from *Sample solution B*'' to: r_{U2} = peak response for cholecalciferol from *Sample solution B* r_{IS2} = peak response for ergocalciferol from *Sample solution B* r_{IS1} = peak response for ergocalciferol from *Sample solution A* r_{U1} = peak response for cholecalciferol from *Sample solution A*
2881	*Ecamsule Solution*	*Impurities Organic Impurities*	1st formula under *Procedure 1: Test for Related Compounds A to F*: Change ''Result = $(r_U/r_S) \times [C_S/(C_U \times A)] \times 100$'' to: Result = $(r_U/r_S) \times [(100 \times C_S)/(C_U \times A)] \times 100$
			2nd formula under *Procedure 1: Test for Related Compounds A to F*: Change ''Result = $(r_U/r_S) \times [C_S/(C_U \times A)] \times (M_{r1}/M_{r2}) \times 100$'' to: Result = $(r_U/r_S) \times [(100 \times C_S)/(C_U \times A)] \times (M_{r1}/M_{r2}) \times 100$
			1st formula under *Procedure 2: Test for Related Compound G, Ecamsule exo-2-Hydroxyecamsule, Ecamsule endo-2-Hydroxyecamsule, and Unspecified Impurities*: Change ''Result = $(r_U/r_S) \times [C_S/(C_U \times A)] \times (M_{r1}/M_{r2}) \times 100$'' to: Result = $(r_U/r_S) \times [(100 \times C_S)/(C_U \times A)] \times (M_{r1}/M_{r2}) \times 100$
			2nd formula under *Procedure 2: Test for Related Compound G, Ecamsule exo-2-Hydroxyecamsule, Ecamsule endo-2-Hydroxyecamsule, and Unspecified Impurities*: Change ''Result = $(r_U/r_S) \times (C_S/C_U \times A) \times (1/F) \times 100$'' to: Result = $(r_U/r_S) \times [(100 \times C_S)/(C_U \times A)] \times (1/F) \times 100$
4368	*Polyvinyl Alcohol*	*Impurities Organic Impurities*	Line 1 under *Procedure 2: Limit of Methanol (Methyl Alcohol) and Methyl Acetate, System suitability*: Change ''*Sample: Sample solution*'' to: *Sample: Standard solution*
4735	*Succinylcholine Chloride*	*Impurities Organic Impurities*	Line 1 under *Procedure 1*: *Solution A*: Change ''3.85 mg/mL of 1-pentanesulfonic acid,'' to: 3.85 mg/mL of sodium 1-pentanesulfonate anhydrous,